ホーム › 濾胞性リンパ腫 › テキサス › Houston
Houston、TXにおける濾胞性リンパ腫の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、濾胞性リンパ腫に関する18件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
被験者募集中観察研究
- Texas Children's Hospital, Houston
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
被験者募集中第1/2相
- Research Site, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
被験者募集中第1/2相
- Md Anderson Cancer Center, Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
被験者募集中第1相
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
被験者募集中第2相
- Research Site, Houston
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
被験者募集中第3相
- Center for Oncology and Blood Disorders, Houston
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
被験者募集中第2相
- MD Anderson Cancer Center, Houston
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
被験者募集中第2相
- M D Anderson Cancer Center, Houston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
被験者募集中第3相
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
被験者募集中第1/2相
- University of Texas MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
被験者募集中第1相
- The University of TX MD Anderson Cancer Center, Houston
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
被験者募集中第2相
- Memorial Hermann Hospital / UTHealth McGovern Medical School at Houston, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
被験者募集中第1相
- MD Anderson Cancer Center, Houston
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
被験者募集中第1相
- Oncology Consultants, Houston
- University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Houston
他の都市における濾胞性リンパ腫の試験
- New York City, NY24件の研究
- Milwaukee, WI19件の研究
- Nashville, TN18件の研究
- Boston, MA17件の研究
- Baldwin Park, CA16件の研究
- Seattle, WA15件の研究
- Durham, NC15件の研究
- Columbus, OH13件の研究
- Salt Lake City, UT13件の研究
- Chicago, IL12件の研究
- San Antonio, TX12件の研究
- Philadelphia, PA12件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。